We have previously shown that when we treat poorly metastatic breast cancer tumor cell line MCF7 and primary endothelial cell line human umbilical vein endothelial cells (HUVECs) with cell secretions from miR526b and miR655-overexpressing cells, there is an increase in ROS, SO, and oxidative stress marker thioredoxin reductase 1 (TXNRD1) expression. The gene discussed is TXNRD1; the disease is breast carcinoma.